Investing

Intellia Therapeutics : NTLA

NTLA

Stock Data

$12.11

$0.24 (1.94%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Intellia Therapeutics Inc is at the forefront of genome editing, pioneering the development of treatments with the potential to cure diseases. Their work includes groundbreaking in vivo programs like NTLA-2001, targeting transthyretin amyloidosis, and others aimed at hereditary angioedema and alpha-1 antitrypsin deficiency. Beyond these, Intellia is exploring engineered cell therapies for cancer and autoimmune diseases, leveraging advanced CRISPR/Cas9 technology. Partnerships with leading biotech firms enhance their efforts in hemophilia and CAR-T cell therapies, underscoring their commitment to revolutionizing medicine. Founded in 2014, Intellia's home base is in Cambridge, Massachusetts.

All Intellia Therapeutics Articles

14 Articles

Jeremy Phillips | Apr 12, 2026 at 8:49 AM EDT

Colossal’s Ben Lamm Says Invasive Species Is a $5.4 Trillion Problem. Here’s His Solution

Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That’s according to…

Rich Duprey | Jul 10, 2025 at 10:54 AM EDT

Move Over, Magnificent 7: The Frontier 7 Will Redefine Our Future

Investors have become quite familiar with the Magnificent Seven, the group of tech giants that reshaped markets with their dominance…

Rich Duprey | Jun 15, 2025 at 6:34 AM EDT

Can a $10,000 Investment in CRISPR Therapeutics Turn Into $1 Million?

Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require…

Trey Thoelcke | Aug 6, 2024 at 9:15 AM EDT

Prediction: This Pharma Stock Will Be the Best Performer the Rest of 2024

Market pullbacks can make nervous investors leery of investing in industries that are more speculative. Wall Street still has big…

Lee Jackson | Mar 15, 2023 at 8:51 AM EDT

Wednesday’s Top Analyst Upgrades and Downgrades: Charles Schwab, GE, GitLab, Home Depot, Match, SoFi, United Airlines and More

Wednesday's top analyst upgrades and downgrades included Academy Sports and Outdoors, Asana, Charles Schwab, Estee Lauder, General Electric, GitLab, Home…

Lee Jackson | Jan 25, 2023 at 8:53 AM EST

Wednesday’s Top Analyst Upgrades and Downgrades: Amazon, Caesars, Dollar Tree, DraftKings, IBM, Lyft, Marathon Oil, McDonald’s, Starbucks, Target and More

Wednesday's top analyst upgrades and downgrades included Amazon.com, Blackstone, Caesars Entertainment, Dollar Tree, DraftKings, GlobalFoundries, IBM, Lyft, Marathon Oil, McDonald's,…

Lee Jackson | Sep 22, 2022 at 8:43 AM EDT

Thursday’s Top Analyst Upgrades and Downgrades: AutoZone, CrowdStrike, Estee Lauder, Morgan Stanley, Nvidia, Western Digital and More

Thursday’s top analyst upgrades and downgrades included AutoZone, CrowdStrike, Estee Lauder, Morgan Stanley, Nvidia and Western Digital.

Lee Jackson | Jun 17, 2022 at 8:43 AM EDT

Friday’s Top Analyst Upgrades and Downgrades: Amgen, AutoZone, Boeing, Dollar General, Etsy, FedEx, Unity Software, Warner Bros. Discovery and More

Friday's top analyst upgrades and downgrades included Acadia Pharmaceuticals, Accenture, Amgen, AutoZone, Azek, Boeing, Dollar General, Etsy, Fidelity National Information…

Lee Jackson | Feb 8, 2022 at 8:54 AM EST

Tuesday’s Top Analyst Upgrades and Downgrades: Apple, Continental Resources, Bilibili, Eaton, Hershey, Meta Platforms, Nio, NOV, PayPal, Southern Company and More

Tuesday's top analyst upgrades and downgrades included Apple, Continental Resources, Bilibili, Eaton, Hershey, Meta Platforms, Nio, NOV, PayPal and Southern…

Chris Lange | Sep 24, 2021 at 11:50 AM EDT

Friday Afternoon Analyst Upgrades and Downgrades: Barrick Gold, Newmont, Salesforce and More

Friday afternoon's analyst upgrades and downgrades included Barrick Gold, Canadian National Railway, Community Health Systems, Editas Medicine, Intellia Therapeutics, Newmont…

Chris Lange | Jun 29, 2021 at 8:05 AM EDT

Why Cramer Thinks Companies Should Not Aspire to Meme Stock Status

24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.

Chris Lange | Jun 11, 2021 at 9:08 AM EDT

Friday’s Top Analyst Upgrades and Downgrades: Biogen, CME, Dropbox, DocuSign, Nvidia, Tilray and More

Friday's top analyst upgrades and downgrades included Biogen, CME, Dropbox, DocuSign, Nvidia, Ping Identity, Signet Jewelers and Tilray.

Chris Lange | May 7, 2021 at 12:10 PM EDT

Etsy, Monster Beverage, Nokia and More Friday Afternoon Analyst Calls

24/7 Wall St. looks at some big analyst calls that we have seen so far on Friday, including Etsy, Fate…

Chris Lange | May 4, 2021 at 12:16 PM EDT

Domino’s, Editas, Roblox, Teva, US Steel and More Tuesday Afternoon Analyst Calls

24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Domino’s Pizza,…